**8. Anticancer boron compounds**

Cancer is the disease that reduces the life quality of patients the most and causes the highest rate of death in the world. For this reason, intensive scientific research continues on strategies that will both improve the quality of life of patients and treat the disease. Boronic acid, bortezomib, talabostat, and boron nitride capture therapy are important boron-containing candidates for anticancer therapy. Bortezomib is a 26S proteosoma inhibitor and activates NF-κB. This process enhances apoptotic mechanism in the cells. Boronic acid is used as an anticancer agent via ROS modulation in the cells. It has been demonstrated that boronic acid prodrugs significantly induce apoptosis in primary leukemic lymphocytes [40]. Bortezomib was approved by US Food and Drug Administration (FDA) in 2003, and at the present time, it is used for chemotherapy of multiple myeloma and mantle cell lymphoma, but peripheral neuropathy is one of the common adverse effects of Bortezomib [41].
